Skip to content
OpenCapital
Get started

Citius Oncology, Inc. CTOR Increase (Decrease) in Inventories

Increase (Decrease) in Inventories at other companies

Gilead Sciences logo
Gilead SciencesGILD
——

Other financials

Income statement

See full
Revenue$1.7M—
Gross profit$1.3M—
Operating income-$28.6M-283%
Net income-$26.6M-244%
EPS (diluted)-$0.27-145%

Balance sheet

See full
Cash & equivalents$2.6M+2,350,466%
Total equity$35.3M-1.0%
Total assets$100.7M+10.1%

Cash flow

See full
Operating cash flow-$3.8M-179%

Valuation

See full
Market cap$60.45M-74.7%

Returns & leverage

See full
Return on equity-119.9%+46.7pp
Current ratio0.5×+0.1×

Where this comes from

Reported directly by Citius Oncology, Inc. in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInInventories.

The official record: Citius Oncology, Inc.’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →

Ask your AI about Citius Oncology, Inc.'s increase (decrease) in inventories.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Citius Oncology, Inc.'s increase (decrease) in inventories?
Citius Oncology, Inc. (CTOR) reported increase (decrease) in inventories of $20.25K in Q1 2026.
How has Citius Oncology, Inc.'s increase (decrease) in inventories changed year-over-year?
Citius Oncology, Inc.'s increase (decrease) in inventories decreased by 97.9% year-over-year, from $957.88K to $20.25K.
What does increase (decrease) in inventories mean?
Measures the net change in inventory levels during the reporting period, reflecting the balance between production, procurement, and sales. An increase typically indicates investment in stock to meet future demand, while a decrease may signal inventory liquidation or efficient supply chain management. It is a critical component of working capital analysis.